Amgen Urges Court to Block Novartis Neupogen Biosimilar Launch

Amgen Inc. is seeking a preliminary injunction against Sandoz, a subsidiary of Novartis AG, over its application for the biosimilar version of Amgen’s blockbuster drug, Neupogen.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news